Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning
| Autor: | Johannes H L M van Groenendael, Gerard Collée, Gülşah Akdemir, Sytske Anne Bergstra, Otto Olivas, Robert Landewé, N. Riyazi, Cornelia F Allaart |
|---|---|
| Přispěvatelé: | AII - Inflammatory diseases, Clinical Immunology and Rheumatology, Amsterdam institute for Infection and Immunity |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty lcsh:Diseases of the musculoskeletal system Treatment intensification Early rheumatoid arthritis Arthritis Rheumatoid Disease activity 03 medical and health sciences 0302 clinical medicine Physical functioning Prednisone Internal medicine Low disease activity Humans Multicenter Studies as Topic Medicine 030212 general & internal medicine Functional ability Aged Randomized Controlled Trials as Topic 030203 arthritis & rheumatology business.industry Remission Induction Middle Aged medicine.disease Rheumatology Treatment Methotrexate Treatment Outcome Antirheumatic Agents Rheumatoid arthritis Orthopedic surgery Physical therapy Drug Therapy Combination Female lcsh:RC925-935 business Research Article medicine.drug |
| Zdroj: | Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-6 (2017) Arthritis research & therapy, 19(1). BioMed Central Arthritis Research and Therapy, 19 Arthritis Research & Therapy |
| ISSN: | 1478-6354 |
| Popis: | Background It is recommended to optimise treatment as long as a predefined treatment target is not met, but should the aim be remission if patients are in low disease activity (LDA)? The aim of this study was to assess if, in patients with rheumatoid arthritis (RA) or patients with undifferentiated arthritis (UA) with Disease Activity Score (DAS) ≤ 2.4 (LDA), treatment intensification results in better functional ability. Methods In the IMPROVED study 610 patients with early RA or UA were treated with methotrexate + tapered high-dose prednisone. After 4 months, patients with DAS ≥ 1.6 were randomised to either of two treatment strategies. Patients with DAS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink